Back to Results
First PageMeta Content
Budesonide/formoterol / Phenols / Piperazines / Receptor antagonist / Formoterol / Zolmitriptan / Quetiapine / 4Q / Chemistry / Organic chemistry / Pharmacology


Document Date: 2013-10-05 07:06:42

Open Document

Share Result on Facebook

Company

AstraZeneca / /

Event

FDA Phase / /

Facility

AstraZeneca R&D Pipeline / Infection II AstraZeneca R&D Pipeline / /

IndustryTerm

Prevention of stroke / /

MedicalCondition

positive infections / CNS disorders / GERD / NSAID derivative Delta opioid NMDA Antagonist Acute /chronic pain Analgesia Acute /chronic / Filed TBD COPD III 3Q / Acute /chronic pain Acute /chronic / II antagonist Hypertension / TBD Asthma/COPD I 1Q / stroke / Premenopausal Adjuvant Breast Cancer III 4Q / reflux disease / Neutropenics Cystic Fibrosis III 3Q / Parkinson’s Disease Huntington’s chorea CNS / /

MedicalTreatment

relaxations / /

NaturalFeature

Na channel / /

Organization

European Union / /

Person

Asthma Asthma III II / Paediatrics Asthma III III / /

Position

candidate for licensing activity AR-R15896 / /

Product

Seroquel / Zomig / Pulmicort / glycine / Accolate / Merrem / Naropin / Nexium / Iressa / naproxen / Arimidex / Symbicort / Faslodex / Atacand / Zestril / Plendil / Casodex / Zoladex / Respiratory Symbicort ®Turbuhaler / Hypertension Atacand® Plus Phase Estimated / /

ProvinceOrState

New Brunswick / /

SocialTag